Drug profile · INN
betamethasone dipropionate
DIPROSONE
betamethasone dipropionate (DIPROSONE) is a glucocorticoid receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — betamethasone dipropionate
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
betamethasone dipropionate (DIPROSONE) is a glucocorticoid receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is betamethasone dipropionate?
betamethasone dipropionate (DIPROSONE) is a glucocorticoid receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for betamethasone dipropionate?
DIPROSONE is a marketed brand name for betamethasone dipropionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of betamethasone dipropionate?
betamethasone dipropionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.